International Journal of Medical and Pharmaceutical Sciences
Open access peer-reviewed Journal
Volume 2, Issue 7, Page 113-122.
https://doi.org/10.5281/zenodo.21238007

Review Article

Design, Optimization, and Characterization of Nano Embedded Losartan Potassium Transdermal Therapeutic System

Kajal Maurya, Shashank Tiwari*, Sadhna Singh

Lucknow Model College of Pharmacy, Lucknow

Hypertension is one of the most common cardiovascular disorders and a major cause of morbidity and mortality worldwide. Losartan potassium, a selective angiotensin II receptor blocker (ARB), is extensively prescribed for the treatment of hypertension, diabetic nephropathy, and cardiovascular complications. However, oral administration of losartan potassium is associated with poor bioavailability due to extensive hepatic first-pass metabolism and variable gastrointestinal absorption. These limitations have encouraged the development of alternative drug delivery systems capable of enhancing therapeutic efficacy and patient compliance. Transdermal drug delivery systems (TDDS) have emerged as a promising alternative because they bypass first-pass metabolism, maintain controlled plasma drug concentrations, reduce dosing frequency, and improve patient adherence. Nevertheless, the stratum corneum presents a significant barrier to drug penetration through the skin. Nanotechnology-based approaches have been investigated extensively to overcome these challenges. Nano-embedded transdermal systems incorporating polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and liposomes have demonstrated improved skin permeation, enhanced bioavailability, controlled drug release, and increased therapeutic effectiveness. The present review provides a comprehensive overview of the design, optimization, and characterization of nano-embedded losartan potassium transdermal therapeutic systems. The formulation strategies, nanocarrier selection, optimization methodologies, evaluation techniques, recent developments, and future perspectives are critically discussed. The integration of nanotechnology with transdermal drug delivery offers significant opportunities for improving antihypertensive therapy and represents a promising area of pharmaceutical research.

Keywords: Losartan potassium, Hypertension, Nanoparticles, Transdermal drug delivery, Nanoemulsion, Solid lipid nanoparticles, Controlled release.

INTRODUCTION

Hypertension is a chronic cardiovascular disorder characterized by persistently elevated arterial blood pressure. According to global health reports, hypertension affects more than one billion people worldwide and remains one of the leading causes of cardiovascular disease, stroke, kidney failure, and premature death. Effective management of hypertension is therefore essential to reduce disease burden and improve patient outcomes. Among the available antihypertensive agents, losartan potassium has gained considerable importance due to its efficacy, safety profile, and ability to selectively block angiotensin II type-1 receptors. Angiotensin II is a potent vasoconstrictor responsible for increased blood pressure, sodium retention, and cardiovascular remodeling. By inhibiting the action of angiotensin II, losartan effectively lowers blood pressure and protects against cardiovascular complications. Despite its clinical usefulness, losartan potassium exhibits several pharmacokinetic limitations when administered orally. The drug undergoes extensive first-pass metabolism in the liver, resulting in reduced systemic bioavailability. Furthermore, fluctuations in plasma drug concentrations may occur due to variable absorption and frequent dosing requirements. These challenges have motivated researchers to investigate alternative drug delivery approaches capable of enhancing therapeutic performance. Transdermal drug delivery systems have emerged as a valuable strategy for improving drug administration. Unlike oral dosage forms, transdermal systems deliver drugs directly through the skin into systemic circulation. This route offers several advantages, including avoidance of gastrointestinal degradation, elimination of hepatic first-pass metabolism, sustained drug release, improved patient compliance, and reduced side effects.

Transdermal Drug Delivery Systems

Transdermal drug delivery refers to the administration of therapeutic agents through intact skin for systemic absorption. The concept was developed to overcome the limitations associated with conventional oral and injectable dosage forms.

A typical transdermal therapeutic system consists of:

- Drug reservoir
- Polymer matrix
- Adhesive layer
- Backing membrane
- Release liner
- Permeation enhancer

The drug is released from the formulation and diffuses through the skin layers before entering systemic circulation.

Losartan Potassium: Pharmaceutical Profile

Chemical Name

Potassium 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl) benzyl] imidazole-5- methanol.

Molecular Formula

C22H22ClKN6O

Molecular Weight

l Approximately 461 g/mo

Category

Angiotensin II Receptor Blocker (ARB)

Mechanism of Action

Losartan selectively blocks angiotensin II type-1 receptors, preventing vasoconstriction and reducing blood pressure.

Indications

- Hypertension
- Diabetic nephropathy
- Heart failure
- Stroke prevention

Rationale for Nano-Embedded Losartan Potassium TDDS

The incorporation of nanotechnology into transdermal systems provides numerous advantages:

Enhanced Skin Permeation

Nano-sized carriers can penetrate skin barriers more effectively.

Improved Drug Solubility

Nanocarriers increase the apparent solubility of poorly soluble drugs.

Controlled Drug Release

Drug release profiles can be tailored according to therapeutic requirements.

Enhanced Stability

Nanoparticles protect drug molecules from degradation.

Improved Bioavailability

Avoidance of first-pass metabolism improves systemic drug exposure.

Reduced Dosing Frequency

Sustained release systems maintain therapeutic concentrations for extended periods.

Nanocarriers Used In Losartan Potassium Transdermal Therapeutic Systems

Nanocarriers are submicron-sized delivery systems designed to improve drug solubility, stability, bioavailability, and therapeutic performance. Various nanocarriers have been investigated for the transdermal delivery of losartan potassium.

Polymeric Nanoparticles

Polymeric nanoparticles are colloidal carriers prepared using biodegradable and biocompatible polymers. These systems can entrap drugs within polymer matrices or adsorb them onto their surfaces.

Commonly Used Polymers

- Poly (lactic-co-glycolic acid) (PLGA)
- Chitosan
- Eudragit Polycaprolactone (PCL)
- Sodium alginate

Advantages

- High stability
- Controlled drug
- Enhanced skin penetration
- Improved bioavailability
- Reduced toxicity

Disadvantages

- Complex manufacturing process
- Possible polymer degradation issues

Polymeric nanoparticles have shown significant potential in achieving prolonged antihypertensive activity through controlled transdermal delivery.

Solid Lipid Nanoparticles (SLNs)

Solid lipid nanoparticles are composed of physiological lipids that remain solid at both room and body temperature.

Components

- Solid lipids
- Surfactants
- Co-surfactants

Common Lipids

- Glyceryl monostearate
- Stearic acid
- Cetyl palmitate
- Compritol

Advantages

- Biocompatibility
- Low toxicity
- Controlled drug release
- Protection against degradation I
- improved skin adhesion

Limitations

- Limited drug loading
- Drug expulsion during storage

SLNs are widely explored because their lipid composition closely resembles skin lipids, facilitating permeation through the stratum corneum.

Nanostructured Lipid Carriers (NLCs)

Nanostructured lipid carriers represent the second generation of lipid-based nanoparticles.

NLCs consist of:

- Solid lipids
- Liquid lipids (oils)

The presence of liquid lipids creates imperfections within the crystal lattice, allowing higher drug loading.

Advantages

- Greater drug loading capacity
- Reduced drug leakage
- Better stability
- Enhanced skin permeation
- Improved sustained release

Importance in Losartan Delivery

Several studies have demonstrated that NLC-based transdermal systems significantly improve losartan permeation and prolong antihypertensive activity.

Nanoemulsions

Nanoemulsions are kinetically stable dispersions with droplet sizes generally ranging from 20–200 nm.

Types

- Oil-in-water (O/W)
- Water-in-oil (W/O)
- Bicontinuous systems

Components

- Oil phase
- Water phase
- Surfactants
- Co-surfactants

Advantages

- High drug solubilization
- Enhanced permeation
- Ease of preparation
- Improved stability

Mechanism of Enhanced Permeation

Nanoemulsions fluidize skin lipids and increase drug partitioning into the stratum corneum, thereby enhancing penetration.

Comparison of Nanocarriers Used for Losartan Potassium TDDS

Table: 1 Comparison Of Nanocarriers Used For Losartan Potassium TDDS

Nanocarrier	Advantages
polymeric Nanoparticles	Controlled release, stability
SLNs	Biocompatibility, skin penetration
NLCs	High loading, better stability
Nanoemulsions	High permeation, easy preparation
Liposomes	Biocompatibility, hydration High production cost

Formulation Design Of Nano-Embedded Losartan Potassium Patches

The design of a successful transdermal system depends on the careful selection of formulation components and manufacturing parameters.

Drug Selection

An ideal candidate for transdermal delivery should possess:

- Low molecular weight
- Adequate lipophilicity
- High potency
- Good stability

Losartan potassium satisfies many of these requirements and can be further optimized through nanocarrier incorporation.

Polymer Selection

Polymers form the matrix of the transdermal patch.

Common Polymers

Hydrophilic Polymers

- HPMC
- PVP
- Sodium alginate

Hydrophobic Polymers

- Ethyl cellulose
- Eudragit
- Polycaprolactone

Desired Characteristics

- Biocompatibility
- Mechanical strength
- Stability
- Controlled release capability

Optimization of Nano-Embedded Losartan Potassium Systems

Optimization is critical for obtaining formulations with desired quality attributes.

Quality Target Product Profile (QTPP)

The QTPP defines the intended quality characteristics of the product.

Examples

- Particle size below 200 nm
- High entrapment efficiency
- Sustained drug release
- Good physical stability

Critical Quality Attributes (CQAs)

CQAs directly influence product performance.

- Examples
- Particle size
- Zeta potential
- Drug content
- Entrapment efficiency
- Release profile

Critical Material Attributes (CMAs)

CMAs refer to raw material properties affecting formulation quality. Examples

- Lipid concentration
- Polymer concentration
- Surfactant concentration

Critical Process Parameters (CPPs)

CPPs are manufacturing variables influencing product quality. Examples

- Stirring speed
- Sonication time
- Homogenization pressure
- Drying temperature

Quality by Design (QbD)

Quality by Design is a scientific and risk-based approach recommended by regulatory authorities.

Benefits

- Better process understanding
- Reduced batch failures
- Improved product quality
- Regulatory flexibility

QbD Workflow

- Define QTPP
- Identify CQAs
- Risk Assessment
- Experimental Design
- Control Strategy
- Continuous Improvement

Design of Experiments (DoE)

DoE allows systematic investigation of formulation variables.

Advantages

- Reduced experimental runs
- Statistical optimization
- Identification of interactions

Box-Behnken Design (BBD)

Box-Behnken Design is widely used for optimization of nanoformulations.

Independent Variables

- Lipid concentration
- Surfactant concentration
- Homogenization speed

Dependent Variables

- Particle size
- Entrapment efficiency
- Drug release

Benefits

- Efficient optimization
- Reduced number of experiments

- High prediction accuracy

Response Surface Methodology (RSM)

RSM is employed to evaluate relationships between variables and responses.

Applications

- Optimization of particle size
- Drug release kinetics
- Permeation enhancement
- Entrapment efficiency improvement

Table 2: Optimization Parameters

Parameter	Desired Outcome
Particle Size	<200 nm
PDI	<0.3
Zeta Potential	±30 mV
Entrapment Efficiency	>80%
Drug Release	Sustained
Stability	High

Characterizations Of Nano-Embedded Losartan Potassium Transdermal Systems

Characterization is an essential step in the development of nano-embedded transdermal systems. It ensures product quality, stability, safety, and therapeutic efficacy.

Particle Size Analysis

Particle size is one of the most critical parameters affecting skin permeation and drug release behavior.

Importance

- Influences penetration through skin layers.
- Affects drug release kinetics.
- Determines formulation stability.

Method

Dynamic Light Scattering (DLS) is commonly used for particle size determination.

Desired Range

Nanoparticles: 10–200 nm
Nanoemulsions: 20–200 nm
Smaller particles generally provide better permeation through the start um corneum.

Polydispersity Index (PDI) PDI

indicates particle size distribution. Interpretation

An ideal nanoformulation should possess a PDI below 0.3.

PDI Value	Interpretation
<0.1	Highly uniform
0.1–0.3	Acceptable
>0.3.	istribution

Evaluation of Transdermal Patches

Physical Appearance The patch should be:

- Smooth
- Uniform
- Flexible
- Free from air bubbles

Thickness Measurement

- Measured using a digital micrometer.
- Uniform thickness ensures reproducible drug release.

Folding Endurance

- Indicates mechanical strength.

- A patch is repeatedly folded until breakage occurs.
- Higher folding endurance indicates greater flexibility.

In-Vitro Drug Release Studies

In-vitro drug release studies evaluate drug release behavior under controlled laboratory conditions.

Equipment

- Franz Diffusion Cell

Parameters Evaluated

- Drug release rate
- Release kinetics
- Sustained release behavior

Common Kinetic Models

- Zero-order kinetics
- First-order kinetics
- Higuchi model
- Korsmeyer-Peppas model

Stability Studies

Stability testing is conducted according to ICH guidelines.

Storage Conditions

Accelerated Studies

- 40°C ± 2°C / 75% RH ± 5%

Long-Term Studies

- 25°C ± 2°C / 60% RH ± 5%

Parameters Monitored

- Particle size
- Drug content
- Entrapment efficiency
- physical appearance

Recent Research Advances

Recent advances in nanotechnology have significantly improved transdermal drug delivery systems.

Nanostructured Lipid Carriers

Provide higher drug loading and improved permeation.

Hybrid Nanoparticles

Combine advantages of polymeric and lipid-based systems.

Microneedle-Assisted Delivery

Creates microchannels that facilitate drug transport.

Stimuli-Responsive Systems

Release drugs in response to:

- Temperature
- pH
- Light
- Magnetic field

Artificial Intelligence in Formulation Design

AI-based models are increasingly being used to optimize nanoformulations and predict drug release patterns.

FUTURE PERSPECTIVES

Future research should focus on:

- Clinical evaluation of nano-transdermal systems.
- Scale-up production methods.
- Commercial manufacturing.
- Smart transdermal patches.
- Personalized medicine approaches.
- AI-assisted formulation development.

The integration of nanotechnology with digital health devices may revolutionize antihypertensive therapy.

CONCLUSION

Losartan potassium remains an important antihypertensive drug; however, its oral administration is associated with limitations such as first-pass metabolism and reduced bioavailability. Nano-embedded transdermal therapeutic systems offer a promising alternative approach by enhancing skin permeation, improving drug stability, providing controlled drug release, and increasing patient compliance. Nanocarriers including polymeric nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions, and liposomes have demonstrated significant potential in improving transdermal delivery of losartan potassium. Optimization strategies such as Quality by Design, Design of Experiments, and Response Surface Methodology facilitate the development of robust formulations. Comprehensive characterization techniques ensure quality, safety, and efficacy. Future advances in nanotechnology, smart delivery systems, and personalized medicine are expected to further expand the clinical utility of nano-embedded transdermal therapeutic systems for hypertension management.

REFERENCES

1. Thakur, R., Anwer, M. K., Shams, M. S., Ali, A., Khar, R. K., & Shakeel, F. (2009). Proniosomal transdermal therapeutic system of losartan potassium: Development and pharmacokinetic evaluation. Journal of Drug Targeting, 17(6), 442–449.
2. Shams, M. S., Alam, M. I., Ali, A., Sultana, Y., Aqil, M., & Shakeel, F. (2010). Pharmacodynamics of a losartan transdermal therapeutic system for the treatment of hypertension. Drug Development and Industrial Pharmacy, 36(4), 385–392.
3. Shams, M. S., Alam, M. I., Ali, A., Sultana, Y., Aqil, M., & Shakeel, F. (2010). Pharmacokinetics of losartan potassium released from a transdermal therapeutic system. Pharmazie, 65(9), 679–682.
4. Chen, Y. S., Sun, Y. Y., Qin, Z. C., Zhang, S. Y., Chen, W. B., & Liu, Y. Q. (2022). Losartan potassium and verapamil hydrochloride compound transdermal drug delivery system: Formulation and characterization. International Journal of Molecular Sciences, 23(21), 13051.
5. Baviskar, D. T., Parik, V. B., Gupta, H. N., Maniyar, A. H., & Jain, D. K. (2012). Design and evaluation of patches for transdermal delivery of losartan potassium. PDA Journal of Pharmaceutical Science and Technology, 66(2), 126–135.
6. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. Nature Biotechnology, 26(11), 1261–1268.
7. Barry, B. W. (2001). Novel mechanisms and devices to enable successful transdermal drug delivery. European Journal of Pharmaceutical Sciences, 14(2), 101–114.
8. Tiwari, D., & Talreja, S. (2020). A pharmaceutical and pharmacological study of Ficus religiosa: A systematic review. International Journal of Pharmacy and Technology, 12, 7109-7121.
9. Tiwari, S., & Talreja, M. S. (2020). Powder X-ray crystallography-a powerful tool of analysis and identification. Int J Anal Exp Modal Anal, 12, 109-116.
10. Tiwari, D. S., & Talreja, S. (2023). Health benefits of cranberries: An in-depth overview. Health Science Journal, 17(9), 1-6.
11. Ita, K. (2015). Transdermal delivery of drugs with microneedles. Pharmaceutics, 7(3), 90–105.
12. Hadgraft, J. (2001). Skin, the final frontier. International Journal of Pharmaceutics, 224(1–2), 1–18.
13. Williams, A. C., & Barry, B. W. (2012). Penetration enhancers. Advanced Drug Delivery Reviews, 64, 128–137.
14. Kalia, Y. N., Guy, R. H. (2001). Modeling transdermal drug delivery. Advanced Drug Delivery Reviews, 48(2–3), 159–172.
15. Potts, R. O., & Guy, R. H. (1995). A predictive algorithm for skin permeability. Pharmaceutical Research, 12(11), 1628–1633.
16. Blank, I. H. (1965). Cutaneous barrier. Journal of Investigative Dermatology, 45, 240–246.
17. Tiwari, S., Talreja, M. S., & Pandey, M. S. (2020). A review on use of novel drug delivery systems in herbal medicines. Science and Engineering Journal, 24(8), 190-197.
18. Talreja, S., & Tiwari, S. (2023). A comprehensive review of Aconitum heterophyllum. Journal of Ayurveda and Integrated Medical Sciences, 8(10), 195-201.
19. Talreja, S., & Tiwari, S. (2023). A comprehensive review of Achyranthes aspera: Ethnopharmacology, phytochemistry, and

therapeutic potential. An Int. J. Research in AYUSH and Allied Systems, 10(5), 270-278.

20. Kanikkannan, N., Andega, S., Burton, S., Babu, R. J., & Singh, M. (2004). Formulation and in vitro evaluation of transdermal patches. Drug Development and Industrial Pharmacy, 30(2), 205–212.
21. Guy, R. H. (2010). Current status and future prospects of transdermal drug delivery. Pharmaceutical Research, 27(1), 1–11.
22. Jain, N. K. (2008). Controlled and Novel Drug Delivery. CBS Publishers, New Delhi.
23. Shreya Talreja and Prof. Dr. Shashank Tiwari. From One to Millions: The Revolution of Combinatorial Chemistry. Journal of Analytical Techniques and Research. 6 (2024): 36-42
24. Tiwari, S., & Talreja, S. (2023). A Critical Overview on Casuarina equisetifolia. Pharmacognosy Reviews, 17(34).
25. Vyas, S. P., & Khar, R. K. (2012). Targeted and Controlled Drug Delivery. CBS Publishers, New Delhi.
26. Tiwari, Dr & Singh, Sadhana & Kumari, Sandhya. (2026). A Nutraceutical Approach to Obesity Management Using Madhuca Longifolia And Polyherbal Ingredients. International Journal of Medical & Pharmaceutical Sciences. 2. 28-38. 10.5281/zenodo.20535014.
27. Chien, Y. W. (1992). Novel Drug Delivery Systems. Marcel Dekker, New York.
28. Aulton, M. E. (2018). Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier.
29. Tiwari, Dr & Singh, Sadhana & Kumari, Sandhya. (2026). A Nutraceutical Approach to Obesity Management Using Madhuca Longifolia And Polyherbal Ingredients. International Journal of Medical & Pharmaceutical Sciences. 2. 28-38. 10.5281/zenodo.20535014.
30. Sinko, P. J. (2011). Martin's Physical Pharmacy and Pharmaceutical Sciences. Lippincott Williams & Wilkins.
31. Florence, A. T., & Attwood, D. (2016). Physicochemical Principles of Pharmacy. Pharmaceutical Press.
32. Kumari, Sandhya & Tiwari, Dr & Singh, Sadhana. (2025). From tradition to technology: Herbal remedies in modern acne therapy. World Journal of Biology Pharmacy and Health Sciences. 24. 146-159. 10.30574/wjbphs.2025.24.3.1059.
33. Robinson, J. R., & Lee, V. H. L. (1987). Controlled Drug Delivery: Fundamentals and Applications. Marcel Dekker.
34. Allen, L. V., Popovich, N. G., & Ansel, H. C. (2013). Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Lippincott Williams & Wilkins.
35. Kydonieus, A. F., & Berner, B. (1987). Transdermal Delivery of Drugs. CRC Press.
36. Bhowmik, D., Harish, G., Duraivel, S., & Kumar, K. P. S. (2012). Recent advances in transdermal drug delivery systems. The Pharma Innovation Journal, 1(9), 1–15.
37. Sharma, A., & Sharma, U. S. (1997). Liposomes in drug delivery: Progress and limitations. International Journal of Pharmaceutics, 154(2), 123–140.
38. Müller, R. H., Mäder, K., & Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery – A review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics, 50(1), 161–177.
39. Mehnert, W., & Mäder, K. (2001). Solid lipid nanoparticles: Production, characterization and applications. Advanced Drug Delivery Reviews, 47(2–3), 165–196.
40. Müller, R. H., Radtke, M., & Wissing, S. A. (2002). Nanostructured lipid carriers (NLC) in cosmetic and pharmaceutical applications. Advanced Drug Delivery Reviews, 54(Suppl. 1), S131–S155.
41. Pardeike, J., Hommoss, A., & Müller, R. H. (2009). Lipid nanoparticles (SLN and NLC) in cosmetic and pharmaceutical dermal products. International Journal of Pharmaceutics, 366(1–2), 170–184.
42. Shakeel, F., Ramadan, W., & Shafiq, S. (2009). Solubility and thermodynamic function of losartan potassium in different solvents. Journal of Chemical and Engineering Data, 54(4), 1278–1281.
43. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4(2), 145–160.
44. Patel, D., & Patel, N. (2009). Transdermal drug delivery systems: A review. International Journal of Biopharmaceutical Sciences, 1(1), 20–28.

45. Kumar, L., & Verma, R. (2010). In vitro evaluation of topical gel formulations. Acta Poloniae Pharmaceutica, 67(5), 527–532.
46. Aggarwal, G., Dhawan, S., Harikumar, S. L., & Garg, A. (2012). Development, fabrication and evaluation of transdermal drug delivery systems. International Journal of Pharmaceutical Investigation, 2(1), 2–10.
47. Patel, R. P., Patel, G., & Baria, A. H. (2009). Formulation and evaluation of transdermal patches. International Journal of Pharmaceutical Research, 1(1), 1–5.
48. Gupta, A., & Prajapati, S. K. (2012). Formulation approaches in transdermal drug delivery systems. International Journal of Pharmaceutical Sciences Review and Research, 13(2), 5–12.
49. Khar, R. K., Ahmad, F. J., Jain, G. K., & Ali, A. (2013). Pharmaceutical nanotechnology and novel drug delivery systems. Journal of Pharmaceutical Research, 7(2), 98–106.
50. Patel, M., Shah, P., & Patel, N. (2011). Nanoemulsion: A pharmaceutical review. Systematic Reviews in Pharmacy, 2(1), 24–32.
51. Kumar, S., & Gupta, R. (2013). Polymeric nanoparticles in drug delivery. International Journal of Pharmaceutical Sciences and Research, 4(3), 1005–1016.
52. Bansal, M., & Garg, V. (2012). Pharmaceutical applications of nanotechnology. International Journal of Drug Development and Research, 4(1), 14–25.
53. Singh, B., & Sharma, N. (2013). Nanotechnology in controlled drug delivery. Research Journal of Pharmaceutical, Biological and Chemical Sciences, 4(2), 1120–1130.
54. Dash, S., Murthy, P. N., Nath, L., & Chowdhury, P. (2010). Kinetic modeling on drug release from controlled drug delivery systems. Acta Poloniae Pharmaceutica, 67(3), 217–223.
55. Higuchi, T. (1963). Mechanism of sustained-action medication: Theoretical analysis of rate of release of solid drugs. Journal of Pharmaceutical Sciences, 52(12), 1145–1149.
56. Korsmeyer, R. W., Gurny, R., Doelker, E., Buri, P., & Peppas, N. A. (1983). Mechanisms of solute release from porous hydrophilic polymers. International Journal of Pharmaceutics, 15(1), 25–35.
57. Costa, P., & Lobo, J. M. S. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13(2), 123–133.
58. ICH. (2003). ICH Q1A(R2): Stability Testing of New Drug Substances and Products. International Council for Harmonisation.
59. ICH. (2005). ICH Q8(R2): Pharmaceutical Development. International Council for Harmonisation.
60. ICH. (2009). ICH Q9: Quality Risk Management. International Council for Harmonisation.
61. ICH. (2008). ICH Q10: Pharmaceutical Quality System. International Council for Harmonisation

Cite: Kajal Maurya, Shashank Tiwari*, Sadhna Singh, Design, Optimization, and Characterization of Nano Embedded Losartan Potassium Transdermal Therapeutic System, Int. J. Med. Pharm. Sci., 2026, 2 (7), 113-122. https://doi.org/10.5281/zenodo.21238007